- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00952484
Safety and Efficacy of Asfotase Alfa in Juvenile Patients With Hypophosphatasia (HPP)
A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of ENB-0040 (Human Recombinant Tissue Nonspecific Alkaline Phosphatase Fusion Protein) in Children With Hypophosphatasia (HPP)
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Asfotase Alfa was formerly referred to as ENB-0040
Hypophosphatasia (HPP) is a life-threatening, genetic, and ultra-rare metabolic disease characterized by defective bone mineralization and impaired phosphate and calcium regulation that can lead to progressive damage to multiple vital organs, including destruction and deformity of bones, profound muscle weakness, seizures, impaired renal function, and respiratory failure. There are no approved disease-modifying treatments for patients with this disease. There is also limited data available on the natural course of this disease over time, particularly in patients with the juvenile-onset form.
Efficacy analyses were prospectively defined in the protocol with a comparison to historical controls. The historical control group came from patients whose characteristics matched as closely as possible the entry criteria for the trial. The control group included all patients who had x-rays within the age range defined by the inclusion criteria of this study (5 to 12 years of age, inclusive, with open growth plates).
The pre-specified plan for analysis was to combine the two asfotase alfa treated groups (asfotase alfa 2 mg/kg subcutaneous (SC) injection three times per week or 3 mg/kg subcutaneous (SC) injection three times per week) and compare them to historical controls.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Manitoba
-
Winnipeg, Manitoba, Canada, R3A 1S1
- The University of Manitoba Health Services Centre
-
-
-
-
Missouri
-
Saint Louis, Missouri, United States, 63131
- Shriners Hospital for Children
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent from parent or legal guardian prior to participation
- Patients > 5 and < 12 years of age with open growth plates at time of enrollment
- Tanner stage of 2 or less indicating pre-pubescence
Documented history of HPP, as evidenced by:
- Presence of HPP-related rickets on skeletal radiographs of the wrist and knee
- Serum alkaline phosphatase (ALP) below age-adjusted normal range
- Plasma PLP at least twice the upper limit of normal
- 25(OH) vitamin D level > 20 ng/mL
- Ability of patient and parent/guardian to comply with study requirements
Exclusion Criteria:
- Serum calcium or phosphorus below age-adjusted normal range
- History of sensitivity to any study drug constituent
- Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the Investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities
- Treatment with an investigational drug within 1 month before start of study drug
- Current enrollment in any other study involving an investigational new drug, device, or treatment for HPP (e.g., bone marrow transplantation)
- Current evidence of a treatable form of rickets
- Prior treatment with bisphosphonates
- Bone fracture or orthopedic surgery within the past 12 months that, in the opinion of the Investigator would interfere with the ability of study patient to comply with study protocol
- Major congenital abnormality other than those associated with HPP
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: 2 mg/kg
2 mg/kg subcutaneous injection three times per week.
|
2 mg/kg subcutaneous injection three times per week for 6 months.
Other Names:
3 mg/kg subcutaneous injection three times per week for 6 months.
Other Names:
|
Active Comparator: 3 mg/kg
3 mg/kg subcutaneous injection three times per week.
|
2 mg/kg subcutaneous injection three times per week for 6 months.
Other Names:
3 mg/kg subcutaneous injection three times per week for 6 months.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Rickets Severity on Skeletal Radiographs From Baseline to Week 24 as Measured by the Radiographic Global Impression of Change (RGI-C) Scale
Time Frame: Baseline and Week 24
|
A 7-point RGI-C (radiographic global impression of change) score was used to rate change in rickets severity.
Only those patients with a minimum score of +2 indicating substantial healing of rickets) were considered responders.
Three pediatric radiologists not affiliated with the conduct of the study performed the ratings.
|
Baseline and Week 24
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in Osteomalacia - Osteoid Thickness (as Measured by Trans-iliac Crest Bone Biopsy)
Time Frame: Baseline and Week 24
|
Change from Baseline to Week 24 in osteoid thickness.
|
Baseline and Week 24
|
Change in Osteomalacia - Osteoid Volume/Bone Volume (as Measured by Trans-iliac Crest Bone Biopsy)
Time Frame: Baseline and Week 24
|
Change from Baseline to Week 24 in osteoid volume/bone volume (%), calculated as the absolute difference of the Baseline and Week 24 percentages.
|
Baseline and Week 24
|
Change in Osteomalacia - Mineralization Lag Time (as Measured by Trans-iliac Crest Bone Biopsy)
Time Frame: Baseline and Week 24
|
Change from Baseline to Week 24 in mineralization lag time.
|
Baseline and Week 24
|
Change in Height (Z-scores)
Time Frame: Baseline and Week 24
|
Change from Baseline to Week 24 in Height Z-Score.
Height Z-Scores assigned based on Centers for Disease Control (CDC) growth charts and methodology.
|
Baseline and Week 24
|
Change in Biomarkers of Asfotase Alfa Activity as Measured by Plasma Inorganic Pyrophosphate (PPi)
Time Frame: Baseline and Week 24
|
Change from Baseline to Week 24 in Plasma PPi
|
Baseline and Week 24
|
Change in Biomarkers of Asfotase Alfa Activity as Measured by Pyridoxal-5'-Phosphate (PLP)
Time Frame: Baseline and Week 24
|
Change from Baseline to Week 24 in Plasma PLP
|
Baseline and Week 24
|
Maximum Serum Concentration of Asfotase Alfa (Cmax).
Time Frame: Study Week 1 (0 to 48 hours post-dose)
|
Maximum serum concentration observed following single dose of asfotase alfa.
|
Study Week 1 (0 to 48 hours post-dose)
|
Time at Maximum Serum Concentration of Asfotase Alfa (Tmax)
Time Frame: Study Week 1 (0 to 48 hours post-dose)
|
Maximum serum concentration observed following single dose of asfotase alfa.
|
Study Week 1 (0 to 48 hours post-dose)
|
Area Under Serum Concentration-time Curve to Last Measurable Concentration of Asfotase Alfa (AUCt)
Time Frame: Study Week 1 (0 to 48 hours post-dose)
|
Area under serum concentration-time curve to last measurable concentration following single dose of asfotase alfa.
|
Study Week 1 (0 to 48 hours post-dose)
|
Maximum Serum Concentration of Asfotase Alfa (Cmax).
Time Frame: Study Week 6 (0 to 48 hours post-dose)
|
Maximum serum concentration observed following multiple doses of asfotase alfa.
|
Study Week 6 (0 to 48 hours post-dose)
|
Time at Maximum Serum Concentration of Asfotase Alfa (Tmax).
Time Frame: Study Week 6 (0 to 48 hours post-dose)
|
Time at maximum serum concentration observed following multiple doses of asfotase alfa.
|
Study Week 6 (0 to 48 hours post-dose)
|
Area Under Serum Concentration-time Curve to Last Measurable Concentration of Asfotase Alfa (AUCt)
Time Frame: Study Week 6 (0 to 48 hours post-dose).
|
Area under serum concentration-time curve to last measurable concentration following multiple doses of asfotase alfa.
|
Study Week 6 (0 to 48 hours post-dose).
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Simmons JH, Rush ET, Petryk A, Zhou S, Martos-Moreno GA. Dual X-ray absorptiometry has limited utility in detecting bone pathology in children with hypophosphatasia: A pooled post hoc analysis of asfotase alfa clinical trial data. Bone. 2020 Aug;137:115413. doi: 10.1016/j.bone.2020.115413. Epub 2020 May 14.
- Whyte MP, Madson KL, Phillips D, Reeves AL, McAlister WH, Yakimoski A, Mack KE, Hamilton K, Kagan K, Fujita KP, Thompson DD, Moseley S, Odrljin T, Rockman-Greenberg C. Asfotase alfa therapy for children with hypophosphatasia. JCI Insight. 2016 Jun 16;1(9):e85971. doi: 10.1172/jci.insight.85971.
- Millan JL, Narisawa S, Lemire I, Loisel TP, Boileau G, Leonard P, Gramatikova S, Terkeltaub R, Camacho NP, McKee MD, Crine P, Whyte MP. Enzyme replacement therapy for murine hypophosphatasia. J Bone Miner Res. 2008 Jun;23(6):777-87. doi: 10.1359/jbmr.071213.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- ENB-006-09
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypophosphatasia (HPP)
-
AlexionEnrolling by invitationHypophosphatasia (HPP)France, Poland, United Kingdom, Germany, Spain, Saudi Arabia, United States, Canada, Russian Federation, Australia, Italy
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Hvidovre University HospitalOdense University HospitalActive, not recruitingHypophosphatasia (HPP)Denmark
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, France, United Kingdom, Canada, Netherlands, Russian Federation, Turkey, Australia
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada, United Arab Emirates, United Kingdom
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Taiwan, United Kingdom, Australia, Canada, Germany, Spain
-
Alexion PharmaceuticalsCompletedHypophosphatasia (HPP)United States, Canada
-
Alexion Pharmaceuticals, Inc.RecruitingHypophosphatasiaUnited States, Japan, Italy, Turkey, Australia, Germany, United Kingdom, Argentina, France, Canada, India
-
Alexion Pharmaceuticals, Inc.Not yet recruiting
-
AlexionRecruiting
Clinical Trials on asfotase alfa
-
Alexion PharmaceuticalsWithdrawn
-
Alexion Pharmaceuticals, Inc.RecruitingHypophosphatasiaUnited States, Japan, Italy, Turkey, Australia, Germany, United Kingdom, Argentina, France, Canada, India
-
AlexionRecruiting
-
Alexion PharmaceuticalsCompletedHypophosphatasiaUnited States, Germany
-
Alexion Pharmaceuticals, Inc.Xcenda, LLCActive, not recruitingHypophosphatasiaUnited States
-
Alexion PharmaceuticalsCompleted
-
Alexion PharmaceuticalsApproved for marketingHypophosphatasiaUnited States, France
-
Alexion PharmaceuticalsCompletedHypophosphatasiaUnited States, United Arab Emirates, United Kingdom
-
Alexion PharmaceuticalsCompletedHypophosphatasiaUnited States, Spain, Australia, United Kingdom, Italy, France, Canada, Germany, Japan, Russian Federation, Saudi Arabia, Turkey
-
Translational Research Center for Medical Innovation...Osaka University Graduate School of MedicineCompleted